The Biomarkers Market study analyzes and forecasts the market size across 6 regions and 24 countries for diverse segments including By Product (Consumables, Services, Software), By Type (Safety Biomarkers, Efficacy Biomarkers, Predictive Biomarkers, Surrogate Biomarkers, Pharmacodynamics Biomarkers, Prognostic Biomarkers, Validation Biomarkers), By Application (Diagnostics, Drug Discovery & Development, Personalized Medicine, Disease Risk Assessment, Others), By Disease Indication (Cancer, Infectious Diseases, Immune Disorders, Neurological Disorders, Cardiovascular Disorders, Others).
The Biomarkers Market in 2024 reflects the increasing importance of biomarkers in various aspects of healthcare, including disease diagnosis, prognosis, prediction, and therapeutic monitoring. Biomarkers are measurable indicators of biological processes or responses to therapeutic interventions, and they play a crucial role in personalized medicine, drug development, and precision healthcare delivery. The market encompasses a wide range of biomarkers, including genetic biomarkers, protein biomarkers, metabolic biomarkers, and imaging biomarkers, among others. Biomarkers are utilized across multiple medical disciplines, including oncology, cardiology, neurology, immunology, and infectious diseases, to aid in disease detection, risk assessment, treatment selection, and patient monitoring. Key applications of biomarkers include cancer screening, companion diagnostics, patient stratification for clinical trials, assessment of treatment response, and monitoring of disease progression. The biomarkers market is driven by factors such as the growing prevalence of chronic diseases, advances in biomarker discovery technologies, increasing investments in precision medicine initiatives, and the shift towards value-based healthcare models. Additionally, the integration of artificial intelligence, machine learning, and big data analytics in biomarker research and clinical practice enhances biomarker discovery, validation, and utilization, leading to more accurate diagnosis, targeted therapy, and improved patient outcomes.
A prominent trend in the biomarkers market is the rising demand for personalized medicine and precision diagnostics. As our understanding of disease mechanisms and patient variability grows, there is an increasing emphasis on tailoring medical treatments and interventions to individual patients' characteristics, genetic makeup, and disease profiles. Biomarkers play a crucial role in personalized medicine by serving as indicators of biological processes, disease states, and treatment responses, enabling healthcare providers to make more informed diagnostic and therapeutic decisions. The trend towards personalized medicine drives the development and adoption of biomarker-based diagnostic tests and precision medicine approaches across various medical specialties, shaping the future landscape of healthcare delivery.
A significant driver in the biomarkers market is the advancements in omics technologies and molecular diagnostics. Rapid advancements in genomics, proteomics, metabolomics, and other omics disciplines have revolutionized our ability to identify and characterize biomarkers associated with health and disease. High-throughput sequencing technologies, mass spectrometry platforms, and bioinformatics tools enable comprehensive profiling of biomolecular signatures, facilitating the discovery, validation, and utilization of biomarkers for diagnostic, prognostic, and therapeutic purposes. The increasing adoption of molecular diagnostic techniques in clinical practice drives the demand for biomarker-based tests and assays, fueling innovation and growth in the biomarkers market.
An exciting potential opportunity in the biomarkers market lies in the expansion into point-of-care (POC) and companion diagnostic solutions. With the growing emphasis on personalized medicine and the shift towards decentralized healthcare delivery models, there is a rising demand for rapid, accessible, and cost-effective diagnostic tests that can be performed at the point of care. Biomarker-based POC tests offer advantages such as rapid turnaround times, reduced healthcare costs, and improved patient outcomes by enabling timely diagnosis, monitoring, and treatment optimization. Additionally, there is a growing need for companion diagnostic tests that identify patients likely to respond to specific therapies, guiding personalized treatment decisions and improving therapeutic outcomes. By developing innovative POC and companion diagnostic solutions, companies can capitalize on opportunities to address unmet clinical needs, expand market reach, and drive growth in the biomarkers market.
By Product
By Type
By Application
By Disease Indication
Geographical Analysis
• Deepen your industry insights and navigate uncertainties for strategy formulation, CAPEX, and Operational decisions
• Gain access to detailed insights on the Biomarkers Market, encompassing current market size, growth trends, and forecasts till 2030.
• Access detailed competitor analysis, enabling competitive advantage through a thorough understanding of market players, strategies, and potential differentiation opportunities
• Stay ahead of the curve with insights on technological advancements, innovations, and upcoming trends
• Identify lucrative investment avenues and expansion opportunities within the Biomarkers Market industry, guided by robust, data-backed analysis.
• Understand regional and global markets through country-wise analysis, regional market potential, regulatory nuances, and dynamics
• Execute strategies with confidence and speed through information, analytics, and insights on the industry value chain
• Corporate leaders, strategists, financial experts, shareholders, asset managers, and governmental representatives can make long-term planning scenarios and build an integrated and timely understanding of market dynamics
• Benefit from tailored solutions and expert consultation based on report insights, providing personalized strategies aligned with specific business needs.
TABLE OF CONTENTS
1 Introduction to 2024 Biomarkers Market
1.1 Market Overview
1.2 Quick Facts
1.3 Scope/Objective of the Study
1.4 Market Definition
1.5 Countries and Regions Analyzed
1.6 Units, Currency, and Conversions
1.7 Industry Value Chain
2 Research Methodology
2.1 Market Size Estimation
2.2 Sources and Research Methodology
2.3 Data Triangulation
2.4 Assumptions and Limitations
3 Executive Summary
3.1 Global Biomarkers Market Size Outlook, $ Million, 2021 to 2030
3.2 Biomarkers Market Outlook by Type, $ Million, 2021 to 2030
3.3 Biomarkers Market Outlook by Product, $ Million, 2021 to 2030
3.4 Biomarkers Market Outlook by Application, $ Million, 2021 to 2030
3.5 Biomarkers Market Outlook by Key Countries, $ Million, 2021 to 2030
4 Market Dynamics
4.1 Key Driving Forces of Biomarkers Market Industry
4.2 Key Market Trends in Biomarkers Market Industry
4.3 Potential Opportunities in Biomarkers Market Industry
4.4 Key Challenges in Biomarkers Market Industry
5 Market Factor Analysis
5.1 Competitive Landscape
5.1.1 Global Biomarkers Market Share by Company
5.1.2 Product Offerings by Company
5.2 Porter’s Five Forces Analysis
6 Growth Outlook Across Scenarios
6.1 Growth Analysis-Case Scenario Definitions
6.2 Low Growth Scenario Forecasts
6.3 Reference Growth Scenario Forecasts
6.4 High Growth Scenario Forecasts
7 Global Biomarkers Market Outlook By Segments
7.1 Biomarkers Market Outlook by Segments
By Product
Consumables
Services
Software
By Type
Safety Biomarkers
Efficacy Biomarkers
Predictive Biomarkers
Surrogate Biomarkers
Pharmacodynamics Biomarkers
Prognostic Biomarkers
Validation Biomarkers
By Application
Diagnostics
Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Others
By Disease Indication
Cancer
Infectious Diseases
Immune Disorders
Neurological Disorders
Cardiovascular Disorders
Others
8 North America Biomarkers Market Analysis And Outlook To 2030
8.1 Introduction to North America Biomarkers Markets in 2024
8.2 North America Biomarkers Market Size Outlook by Country, 2021-2030
8.2.1 United States
8.2.2 Canada
8.2.3 Mexico
8.3 North America Biomarkers Market size Outlook by Segments, 2021-2030
By Product
Consumables
Services
Software
By Type
Safety Biomarkers
Efficacy Biomarkers
Predictive Biomarkers
Surrogate Biomarkers
Pharmacodynamics Biomarkers
Prognostic Biomarkers
Validation Biomarkers
By Application
Diagnostics
Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Others
By Disease Indication
Cancer
Infectious Diseases
Immune Disorders
Neurological Disorders
Cardiovascular Disorders
Others
9 Europe Biomarkers Market Analysis And Outlook To 2030
9.1 Introduction to Europe Biomarkers Markets in 2024
9.2 Europe Biomarkers Market Size Outlook by Country, 2021-2030
9.2.1 Germany
9.2.2 France
9.2.3 Spain
9.2.4 United Kingdom
9.2.4 Italy
9.2.5 Russia
9.2.6 Norway
9.2.7 Rest of Europe
9.3 Europe Biomarkers Market Size Outlook By Segments, 2021-2030
By Product
Consumables
Services
Software
By Type
Safety Biomarkers
Efficacy Biomarkers
Predictive Biomarkers
Surrogate Biomarkers
Pharmacodynamics Biomarkers
Prognostic Biomarkers
Validation Biomarkers
By Application
Diagnostics
Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Others
By Disease Indication
Cancer
Infectious Diseases
Immune Disorders
Neurological Disorders
Cardiovascular Disorders
Others
10 Asia Pacific Biomarkers Market Analysis And Outlook To 2030
10.1 Introduction to Asia Pacific Biomarkers Markets in 2024
10.2 Asia Pacific Biomarkers Market Size Outlook by Country, 2021-2030
10.2.1 China
10.2.2 India
10.2.3 Japan
10.2.4 South Korea
10.2.5 Indonesia
10.2.6 Malaysia
10.2.7 Australia
10.2.8 Rest of Asia Pacific
10.3 Asia Pacific Biomarkers Market size Outlook by Segments, 2021-2030
By Product
Consumables
Services
Software
By Type
Safety Biomarkers
Efficacy Biomarkers
Predictive Biomarkers
Surrogate Biomarkers
Pharmacodynamics Biomarkers
Prognostic Biomarkers
Validation Biomarkers
By Application
Diagnostics
Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Others
By Disease Indication
Cancer
Infectious Diseases
Immune Disorders
Neurological Disorders
Cardiovascular Disorders
Others
11 South America Biomarkers Market Analysis And Outlook To 2030
11.1 Introduction to South America Biomarkers Markets in 2024
11.2 South America Biomarkers Market Size Outlook by Country, 2021-2030
11.2.1 Brazil
11.2.2 Argentina
11.2.3 Rest of South America
11.3 South America Biomarkers Market size Outlook by Segments, 2021-2030
By Product
Consumables
Services
Software
By Type
Safety Biomarkers
Efficacy Biomarkers
Predictive Biomarkers
Surrogate Biomarkers
Pharmacodynamics Biomarkers
Prognostic Biomarkers
Validation Biomarkers
By Application
Diagnostics
Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Others
By Disease Indication
Cancer
Infectious Diseases
Immune Disorders
Neurological Disorders
Cardiovascular Disorders
Others
12 Middle East And Africa Biomarkers Market Analysis And Outlook To 2030
12.1 Introduction to Middle East and Africa Biomarkers Markets in 2024
12.2 Middle East and Africa Biomarkers Market Size Outlook by Country, 2021-2030
12.2.1 Saudi Arabia
12.2.2 UAE
12.2.3 Oman
12.2.4 Rest of Middle East
12.2.5 Egypt
12.2.6 Nigeria
12.2.7 South Africa
12.2.8 Rest of Africa
12.3 Middle East and Africa Biomarkers Market size Outlook by Segments, 2021-2030
By Product
Consumables
Services
Software
By Type
Safety Biomarkers
Efficacy Biomarkers
Predictive Biomarkers
Surrogate Biomarkers
Pharmacodynamics Biomarkers
Prognostic Biomarkers
Validation Biomarkers
By Application
Diagnostics
Drug Discovery & Development
Personalized Medicine
Disease Risk Assessment
Others
By Disease Indication
Cancer
Infectious Diseases
Immune Disorders
Neurological Disorders
Cardiovascular Disorders
Others
13 Company Profiles
13.1 Company Snapshot
13.2 SWOT Profiles
13.3 Products and Services
13.4 Recent Developments
13.5 Financial Profile
List of Companies
Abbott
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Epigenomics AG
F. Hoffmann-La Roche AG
General Electric
Johnson & Johnson Services, Inc.
Merck KGaA
PerkinElmer Inc.
QIAGEN
Siemens Healthineers AG
Thermo Fisher Scientific Inc
Eurofins Scientific
14 Appendix
14.1 Customization Offerings
14.2 Subscription Services
14.3 Related Reports
14.4 Publisher Expertise
By Product
By Type
By Application
By Disease Indication
Geographical Analysis
The global Biomarkers Market is one of the lucrative growth markets, poised to register a 14.5% growth (CAGR) between 2024 and 2032.
Emerging Markets across Asia Pacific, Europe, and Americas present robust growth prospects.
Abbott, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Epigenomics AG, F. Hoffmann-La Roche AG, General Electric, Johnson & Johnson Services, Inc., Merck KGaA, PerkinElmer Inc., QIAGEN, Siemens Healthineers AG, Thermo Fisher Scientific Inc, Eurofins Scientific
Base Year- 2023; Estimated Year- 2024; Historic Period- 2018-2023; Forecast period- 2024 to 2030; Currency: USD; Volume